Sanofi is stepping back with its plans for its Covid-19 vaccine based on mRNA. The decision is in place as the rivals Pfizer-BioNTech and Moderna are dominating the vaccine market. Sanofi is a French health care group.
The company on Tuesday announced its plan to take back its Covid-19 vaccine as Pfizer-BioNTech and Moderna are way ahead now in using technology to fight the hazardous virus.
Sanofi Steps Back With Its Covid-19 Vaccine mRNA
Sanofi’s move underlines the challenges in competing with the pharma giants. The Pfizer-BioNTech alliance helped BioNTech to rise from anonymity. Pfizer and BioNTech alliance last year.
1.5 million Pfizer-BioNTech Covid-19 vaccine doses have been administered so far. And with this, it became the largest Covid-19 vaccine maker in the Western world.
Sanofi and a British company are now working on a Covid-19 vaccine based on higher conventional protein. This project is taking place within Sanofi’s partnership with British company GlaxoSmithKline. The trials for the same are underway and include a large number of participants.
Sanofi’s Phase I and II trials for the Covid-19 vaccine based on mRNA showed promising results, with a boost in immunity to a great extent. The company, however, stated that the results are only indicative that this method is promising in vaccine production for influenza and other diseases.
Sanofi gave up on the idea of another Covid-19 vaccine based on mRNA. The Moderna and Pfizer vaccines also work on mRNA technology and are fully approved by the US authorities FDA and the CDC.
Thomas Triomphe, head of the Sanofi Pasteur vaccines division, said,” the results we achieved indicate that the procedure we opted for is working perfectly.”
Thomas added, ” Moderna and Pfizer vaccines also work on the mRNA science. We don’t want to waste wealth and science on creating another similar to those. A mass of people are anyway not accepting the mRNA vaccine shots.” He continued and said, “this is the prime reason why we dropped
the idea of producing another vaccine of the same kind.”
The debate for annual repeated shots was high in the United States, Thomas disagreed with annual repeated vaccine shots. He said that the reports show that antibody count boosts after a third dose is administered, and by the time you have a fourth shot of the vaccine, the antibody count will be sufficient in your body.
The CDC and FDA, after long discussions and debates, approved Pfizer’s booster shots. Americans are already able to book their slots for the third dose of the Pfizer vaccine against Covid-19. Data regarding the booster doses from Moderna and Johnson &Johnson are also under consideration by the US regulators.
Thomas estimated that by mid-2022, as many as 24 billion Covid-19 vaccine doses would have been administered. This large number of administered vaccine shots point towards herd immunity.
Many are seeing Sanofi’s decision of stepping advances towards the mRNA Covid-19 vaccine as a thoughtful decision. The company will be saving on developmental costs and can focus on upcoming new ventures and products.
Some French politicians, however, tarnished Sanofi’s prestige. Questions were raised about its slow progress in developing a Covid-19 vaccine.